PULM - Pulmatrix Inc Stock Price, Fair Value and News

$7.72-0.18 (-2.28%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PULM Price Action

Last 7 days

27.2%


Last 30 days

13.3%


Last 90 days

253.2%


Trailing 12 Months

329.3%

PULM RSI Chart

MayJunJulAugSepOctNovDec20252030405060708090100

PULM Valuation

Market Cap

28.9M

Price/Earnings (Trailing)

-2.99

Price/Sales (Trailing)

2.61

Price/Free Cashflow

-2.37

PULM Price/Sales (Trailing)

202220232024202501K2K3K4K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PULM Fundamentals

PULM Revenue

Revenue (TTM)

11.1M

Rev. Growth (Yr)

-79.12%

Rev. Growth (Qtr)

-86.02%

2016201820202022202402M4M6M8M10M12M

PULM Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

31.45%

Earnings Growth (Qtr)

55.48%

201420162018202020222024-35M-30M-25M-20M-15M-10M-5M0

PULM Profitability

Return on Equity

-88.42%

Return on Assets

-83.89%

Free Cashflow Yield

-42.18%

PULM Investor Care

Diluted EPS (TTM)

-2.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
201520162017201820192020202120222023202402M4M6M8M10M12M
Net sales
YearQ1Q2Q3Q4
202411.7M12.5M11.1M0
20236.4M6.9M6.8M7.3M
20224.9M4.0M4.8M6.1M
202111.3M10.0M6.7M5.2M
202010.6M9.3M12.2M12.6M
201905.0M6.4M8.0M
2018605.5K488.0K153.0K306.0K
201700773.5K513.5K
20161.5M1.6M992.0K834.5K
2015143.0K309.0K930.0K1.2M
2014000352.0K
Get all data in R, Python etc through our Historical Stock Data APIs
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEpulmatrix.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES28

Pulmatrix Inc Frequently Asked Questions


What is the ticker symbol for Pulmatrix Inc? What does PULM stand for in stocks?

PULM is the stock ticker symbol of Pulmatrix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulmatrix Inc (PULM)?

As of Wed Jan 29 2025, market cap of Pulmatrix Inc is 28.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PULM stock?

You can check PULM's fair value in chart for subscribers.

Is Pulmatrix Inc a good stock to buy?

The fair value guage provides a quick view whether PULM is over valued or under valued. Whether Pulmatrix Inc is cheap or expensive depends on the assumptions which impact Pulmatrix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PULM.

What is Pulmatrix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jan 29 2025, PULM's PE ratio (Price to Earnings) is -2.99 and Price to Sales (PS) ratio is 2.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PULM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pulmatrix Inc's stock?

In the past 10 years, Pulmatrix Inc has provided -0.427 (multiply by 100 for percentage) rate of return.